Previous 10 | Next 10 |
Calliditas Therapeutics (CALT): Q3 GAAP EPS of -SEK2.77.Cash of SEK1.4BPress Release For further details see: Calliditas Therapeutics reports Q3 results
Interim Report Q3, 2020 Expansion of pipeline and positive phase 3 topline data PR Newswire STOCKHOLM, Nov. 12, 2020 STOCKHOLM , Nov. 12, 2020 /PRNewswire/ -- "On August 13 th , we announced a €19.8m acquisition of a majority stake of 62.7%...
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report PR Newswire STOCKHOLM, Nov. 11, 2020 STOCKHOLM , Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020 , at 07:00 am CET , Calliditas Therapeutics ("Calliditas"...
SHANGHAI, China, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, ...
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial PR Newswire STOCKHOLM, Nov. 9, 2020 STOCKHOLM , Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020 , Calliditas announced positive topline result...
Calliditas Therapeutics (CALT) announces positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, investigating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN). The analysis included 199 patients. The trial met its primary o...
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial PR Newswire STOCKHOLM, Nov. 9, 2020 STOCKHOLM , Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced p...
Calliditas closes acquisition of a controlling interest in Genkyotex SA PR Newswire STOCKHOLM, Nov. 3, 2020 STOCKHOLM , Nov. 3, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the clo...
Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 PR Newswire STOCKHOLM, Oct. 19, 2020 STOCKHOLM , Oct. 19, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced upcoming presentations concerning Ne...
The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 PR Newswire STOCKHOLM, Oct. 1, 2020 STOCKHOLM , Oct. 1, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas")...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...